Data from a large prospective study identified male and older patients as being more likely to develop CIP and 34% of cases ...

Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI ...

Data from NIAGARA supported the FDA’s approval of neoadjuvant durvalumab in combination with gemcitabine and cisplatin, ...

A preliminary analysis of patient-reported outcomes for emotional functioning (EF) in patients with solid tumors revealed ...

Chemo-induced myelosuppression can affect patients’ ability to do daily tasks, and management varies by patient, treatment ...

On this episode of Onc Nurse On Call, Kristin Daly, MSN, ANP-BC, AOCNP, discusses practical cancer care strategies in the age ...

Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes ...

Panelists discuss how the phase 3 MK-3475-877 trial findings demonstrated subcutaneous pembrolizumab’s pharmacokinetic comparability to intravenous (IV) formulation with similar efficacy (45% vs 42% ...

Learn the critical factors in determining prophylaxis for venous thromboembolism, a frequent and serious complication for ...

Following imlunestrant’s approval, Komal Jhaveri, MD, FACP, compares the oral SERD to its counterpart, elacestrant, in terms of composition and trials.

AI-driven decision support can ease oncologists’ workloads and streamline care without reducing autonomy.